Immunostimulator anti-cancer compounds
OwnerAlain Martininventor
Life of this patent
Estimating the term…
Abstract
The present invention comprises a method for the treatment of cancerous tumors in mammals comprising the administration of an effective amount of an immunostimulator which enhances and potentiates the mammals own immune system to selectively attack and kill the cancerous cells. The immunostimulator, preferably urushiol, is administered in a pharmaceutically acceptable carrier and can be co-administered in conjunction with other immunostimulators, radiation therapy or other cytotoxic anti-cancer agents to further enhance their effect.
Claims8
A method for the treatment of cancerous tumors in a mammal comprising the administration of an effective amount of an immunostimulator in a pharmaceutically acceptable carrier.
A method for the enhancement of the immune system to attack cancerous tumors in a mammal comprising the administration of an effective amount of urushiol in a pharmaceutically acceptable carrier.
A method for the enhancement of cytotoxic anti-cancer agents for the treatment of cancerous tumors in a mammal comprising the administration of an effective amount of urushiol.
A pharmaceutical composition for the treatment of cancerous tumors in a mammal comprising a combination of an effective amount of urushiol and one or more secondary immunostimulator compounds selected from the group consisting of cytokines, tumor-associated proteins and antigens, tumor vaccines, lipopolysaccharides, bacillus Calmette-Guérin, immunoglobulin, alpha-interferon, interleukin-2, synthetic agents such as selected from the group comprising levamisole and isoprinosine and mixtures thereof.
A pharmaceutical composition for the treatment of cancerous tumors in a mammal comprising an effective amount of urushiol and one or more secondary anti-cancer agents selected from the group consisting essentially of adriamycin, radiation, surgery, ultra-sound, photo-reactive compounds, anthracyclines, nitrogen mustards, ethyleneamines, methylmelamines, alkyl-sulfonates, nitrosoureas, triazenes, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodophyllotoxins, antibiotics, tumor-associated proteins and antigens, biological response modifiers, alpha-interferon, platinum coordination complexes, anthracenedione, substituted-ureas, methylhydrazine derivatives, adrenocortical suppressants, adrenocorticosteroids, progestins, estrogens, anti-estrogens, androgens, anti-androgens, solvents that destroy cancer cells causing the release of cancer antigens and mixtures thereof.
Dependencies are inferred from the claim text.